Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 27/07/20221 min de lecture
Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings; Guidance for Industry; Availability
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings." The guidance provides recommendations to sponsors of clinical trials of investigational cancer drugs regarding the inclusion of patients who have not previously received available therapy (commonly referred to as existing treatment options) for their cancer in the non-curative setting. This guidance finalizes the draft guidance of the same title issued on June 24, 2021.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →